Accuracy of Lung Injury Biomarkers in the Initial Investigation of

Status Completed

Clinical Trial Summary

The aim of this study is to investigate the diagnostic and prognostic value of surfactant protein D, Krebs von den Lungen (KL-6), and Chitinase-3-like protein 1 (YKL-40) in the initial investigation of patients hospitalized with suspected pneumonia. This to improve the diagnosis of pneumonia, contribute to a more rapid and accurate antibiotic treatment, and assess disease severity to predict short-term and long-term mortality in community-acquired pneumonia patients.

Clinical Trial Description

Community-acquired pneumonia (CAP) is one of the most common infection diseases in the emergency department (ED). Diagnosis of pneumonia is challenging as symptoms are often weak and nonspecific and the current methods for focal and etiological diagnosis have low sensitivity and specificity and often deliver results after the antibiotic treatment decision has been made. The abundant and restricted expression of surfactant protein D (SP-D) within the lung makes this protein a specific marker for lung disease. Krebs von den Lungen-6 (KL-6) is expressed in the lung and is a diagnostic and prognostic marker of interstitial lung disease. The inflammatory glycoprotein Chitinase-3-like protein 1 commonly known as YKL-40 is associated with severity of interstitial lung disease. The value of these lung injury markers for diagnosing pneumonia needs further investigation. The investigators hypothesize that surfactant protein D, Krebs von den Lungen (KL-6), and Chitinase-3-like protein 1 (YKL-40) have an impact on diagnosing, prognosis, and treatment of patients with verified CAP. The objectives of the study are: - To investigate the diagnostic accuracy of surfactant protein D, Krebs von den Lungen (KL-6), and Chitinase-3-like protein 1 (YKL-40) in the diagnosis of CAP - To identify the prognostic value surfactant protein D, Krebs von den Lungen (KL-6), and Chitinase-3-like protein 1 (YKL-40) in relation to adverse events in patients with verified CAP ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04686331
Study type	Observational
Source	University of Southern Denmark
Contact
Status	Completed
Phase
Start date	March 1, 2021
Completion date	June 1, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05722938` - Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)	Phase 3
Terminated	`NCT04972318` - Two Different Ventilatory Strategies in Acute Respiratory Distress Syndrome Due to Community-acquired Pneumonia	N/A
Recruiting	`NCT06065618` - Characteristics of Hospitalized Patients With Community-acquired Pneumonia
Not yet recruiting	`NCT03675178` - Clinical Study of Anerning Particle for the Treatment of Childhood Community-acquired Pneumonia	Phase 4
Not yet recruiting	`NCT04166110` - Antibiotic Therapy In Respiratory Tract Infections	N/A
Completed	`NCT02380352` - Short-course Antimicrobial Therapy for Paediatric Respiratory Infections	Phase 4
Completed	`NCT01671280` - Drug Use Investigation Of Azithromycin IV For Community-Acquired Pneumonia Or Pelvic Inflammatory Disease (Regulatory Post Marketing Commitment Plan)	N/A
Completed	`NCT02555852` - Proton Pump Inhibitors and Risk of Community-acquired Pneumonia	N/A
Recruiting	`NCT00752947` - Efficacy and Safety Trial to Assess Moxifloxacin in Treating Community-Acquired Pneumonia (CAP) With Aspiration Factors	Phase 4
Completed	`NCT00140023` - Azithromycin Microspheres in Patients With Low Risk Community Acquired Pneumonia	Phase 3
Recruiting	`NCT04089787` - Shortened Antibiotic Treatment of 5 Days in Community-Acquired Pneumonia	Phase 4
Completed	`NCT05356494` - Postural Drainage and PEP Technique in Community Acquired Pneumonia	N/A
Completed	`NCT05133752` - Oral Nemonoxacin in Treating Elderly Patients With CAP	Phase 4
Not yet recruiting	`NCT06291012` - Stopping Pneumonia Antibiotherapy Regimen Early	Phase 4
Recruiting	`NCT05002192` - A Retrospective, Real-world Study of ELP Used in the Expectorant Treatment of Community-acquired Pneumonia
Completed	`NCT03452826` - Combined Use of a Respiratory Broad Panel mPCR and Procalcitonin to Reduce Duration of Antibiotics Exposure in Patients With Severe Community-Acquired Pneumonia	N/A
Terminated	`NCT04071041` - Effect of Albumin Administration in Hypoalbuminemic Hospitalized Patients With Community-acquired Pneumonia.	Phase 3
Completed	`NCT03474991` - KIDS-STEP_Betamethasone Therapy in Hospitalised Children With CAP	Phase 3
Completed	`NCT01723644` - Clinical Reassessment Versus Procalcitonin in Order to Shorten Antibiotic Duration in Community-acquired Pneumonia	N/A
Withdrawn	`NCT01662258` - Microbiology Testing With the Aim Of Directed Antimicrobial Therapy For CAP	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Accuracy of Lung Injury Biomarkers in the Initial Investigation of Patients With Suspected Pneumonia

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms